Preclinical Chemo-Radiotherapy Testing Consortium
PCRTC U01 Program
Introduction
The Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) consists of specialized U01 research projects focused around the shared goal of testing of NCI-prioritized molecularly targeted anti-cancer agents from the CTEP collection (https://ctep.cancer.gov/) that best sensitize tumor cells to standard of care chemoradiation therapies. PCRTC teams were funded through PAR 16-111 To Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (https://grants.nih.gov/grants/guide/pa-files/par-16-111.html) to investigate NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity when combined with chemo-radiotherapy. These pre-clinical studies accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors, with concentration on cancers of the pancreas, lung, head and neck, gastrointestinal tract, and brain.
PCRTC Projects
| Institution (primary site) | MPI Contact | Project Title |
|---|---|---|
| UNIVERSITY OF MICHIGAN AT ANN ARBOR | THEODORE S. LAWRENCE | Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response |
| MASSACHUSETTS GENERAL HOSPITAL | HENNING WILLERS | High-Throughput Screening and Validation of Molecular Targeted Chemoradiosensitizerse |
| MAYO CLINIC ROCHESTER | JANN N. SARKARIA | Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumorse |
| UNIVERSITY OF TX MD ANDERSON CAN CTR | STEVEN HSESHENG LIN | Enhancing Chemoradiation Efficacy through Unbiased Drug Discovery Approaches |
PCRTC Publications
Members of Preclinical Chemo-Radiotherapy Testing Consortium (PCRTC) organized to present viewpoints on enabling new clinical trial concepts in cancer through pre-clinical testing of radiation-drug combinations. The series published in the International Journal of Radiation Oncology-Biology-Physics (see links below) focuses on models and validation methodologies developed through the PCRTC.